Economic analysis of blood pressure control in patients undergoing hemodialysis, am- bulatory cyclical peritoneal dialysis, and automated peritoneal dialysis.

Abstract

Introduction: Blood pressure (BP) control is a fundamental objective in patients with stage 5D chronic kidney disease since hypertension and hypotension adversely affect the patient's quality of life and predispose them to increased cardiovascular risk. This study aimed to conduct an economic analysis of the prescription of antihypertensives in a group of patients undergoing renal function replacement therapy.

Methods: This is a cross-sectional study of the hemodialysis service of the José Carrasco Arteaga hospital. The variables were the type of dialysis, sex, use of antihypertensives, and cost. The sample was non-probabilistic.

Results: 174 patients were analyzed, 73 (41.95%) in a hemodialysis (HD) program, 80 (45.98%) in a manual peritoneal dialysis (PD) program, and 21 (12.07%) in automated peritoneal dialysis (APD). 74% of men were on HD, 39 cases (48.7%) on PD, and 12 cases (57.14%) on DPA. The use of antihypertensives in HD was 84%; in PD, 86%; in DPA, 86%. The cost of antihypertensives was 12.5 ± 8.7 USD in HD, 15.7 ± 22.4 in PD, and 16.4 ± 18.6 USD P>0.05 in CAPD.

Conclusion: The use of antihypertensives in this study group was more than 84% in the different dialysis modalities, with no statistical difference in the cost analysis.